Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
Recruiting
Observational Study
Hepatocellular Carcinoma
Radiotherapy
Treatment Outcome
Biomarkers
Sphingolipids
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 260 (estimated)
- Sponsor
- Nanfang Hospital, Southern Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Plasma contains a variety of metabolites, among which sphingolipids, including ceramide, sphingosine, and sphingosine-1-phosphate, serve as important intracellular second messengers and are involved in various cellular signaling pathways, such as apoptosis. We hypothesize that plasma sphingolipid levels may be associated with the efficacy of radiotherapy for liver cancer. This study will utilize L…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients voluntarily signed the informed consent form.
* Aged between 18 and 80 years.
* Clinically diagnosed with primary liver cancer according to the latest treatment guidelines.
* Determined by the treating physician to require radiotherapy.
* Expected survival time of mor…
Contacts